New Nasal Spray Blocks Flu Virus & Shows Promise Against Bird Flu

A new nasal spray vaccine is showing promise in the fight against bird flu, potentially offering a powerful new tool to prevent infection and limit the spread of the virus. Early research suggests this vaccine could work by stopping the virus before it reaches the lungs, and may even provide broader protection against multiple strains.

The development comes as scientists continue to monitor the evolution of bird flu, also known as H5N1 avian influenza. While cases in humans remain sporadic, the virus has demonstrated an ability to infect a growing number of mammalian species, including cattle in the United States. As of January 29, 2026, bird flu had been detected in 16 commercial and backyard flocks and 33 wild birds across the US, according to Brown’s Pandemic Center. Importantly, there have been no new cases in dairy cattle since mid-December, and no new human cases reported globally.

The nasal spray vaccine, currently in Phase I clinical trials, is designed to stimulate the immune system directly where the virus first enters the body – the nasal passages. This approach differs from traditional flu vaccines, which are typically administered via injection. According to trial data, the spray generated a “strong immune response” in rodents.

One of the key advantages of this new vaccine is its potential to train the immune system to recognize multiple strains of the virus, rather than just one. This could move researchers closer to a “universal flu vaccine” that provides broader protection and reduces the need for annual strain-matching – a process that is often imperfect. The potential for “dose-sparing” is another benefit, meaning that a smaller dose of the vaccine may be effective, which could be crucial for stretching limited stockpiles during a widespread outbreak.

Researchers have been working on this type of vaccine for over two years, recognizing the increasing risk posed by the rapid evolution and expanding footprint of H5N1. The current research builds on a platform that uses an influenza virus vector, and a nasal spray H5N1 avian influenza vaccine has already been developed using this method, as reported in February 4, 2026.

The development of broadly protective, live-attenuated influenza vaccines (LAIV) represents a significant breakthrough. These vaccines offer the potential to protect against both human and avian virus subtypes. Scientists are also exploring other avenues for improving flu vaccines, including engineering antibodies with enhanced staying power and developing needle-free options.

While the current situation appears relatively calm, with no new human cases reported globally recently, experts emphasize the importance of continuing to build better tools to combat bird flu. The time to prepare is during periods of stability, not during a crisis.

Recent research has also highlighted the surprising heat tolerance of bird flu, revealing that a key gene, PB1, allows avian viruses to replicate even at temperatures that would stop human flu viruses. This finding underscores the virus’s adaptability and the need for ongoing vigilance.

The research into this nasal spray vaccine is ongoing, and further trials will be necessary to determine its safety and efficacy in humans. However, the early results are encouraging and suggest that this new approach could play a vital role in preventing future bird flu pandemics.